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Approximately one-third of patients with prostate cancer show prostate-speciﬁc antigen (PSA) recur-
rence (biochemical failure) after a radical prostatectomy and are prone to developing metastasis with
signiﬁcant mortality. Although several clinicopathologic indicators, such as the PSA level, Gleason score,
pathologic stage, and surgical-margin status, are used to predict outcomes after a curative-intended
radical prostatectomy for localized prostate cancer, new biomarkers are still required to improve the
prognosis and plan appropriate adjuvant therapy, particularly for patients at high risk of recurrence.
DNA-based genetic biomarkers have several advantages over clinicopathologic indicators because they
can be preoperatively examined, are easily evaluated, and can be interpreted more objectively without
individual bias. In this study, the literature was reviewed from the PubMed database using the keywords
“genetic polymorphisms” and “radical prostatectomy” from 1985 to April 2011. The results showed that
genetic variants discovered from genome-wide association studies (such as rs1447295, rs1447295,
rs6983561, rs13254738, Broad11934905, rs6983267, and rs7000448 at 8q24, rs7920517 and rs10993994
at 10q11, rs10486567 in the 7JAZF1, rs198977 in the KLK2, rs9282861 in the SULT1A1, and rs1536889 in
the TLR4 gene) and single-nucleotide polymorphisms (SNPs) in important pathways (RUNX1, FGFR4,
EGFR, VEGF, TNFRSF11B, vitamin D receptor, p53, WNT, inﬂammatory, androgen synthesis, and metab-
olism pathways) on prostate cancer occurrence and progression could serve as biomarkers to predict PSA
recurrence after a radical prostatectomy. Including the genetic information might improve predictions of
PSA recurrence after a radical prostatectomy. Future studies can be dedicated to conﬁrming these
ﬁndings in other ethnic cohorts and clarifying the roles of these SNPs/genes in the course of prostate
cancer progression after a radical prostatectomy through functional analyses.
Copyright  2012, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Prostate cancer is the most common type of cancer and the
second leading cause of cancer deaths among American men.1
In Taiwan, the incidence of prostate cancer has been rapidly
increasing in the past decades. It has become the seventh mostaohsiung Medical University
.
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ciation. Published by Elsevier Taiwcommon cause of cancer deaths and resulted in 892 deaths in 2008
(Department of Health, Taiwan). However, its etiology remains
poorly understood. The incidence and mortality rates of prostate
cancer vary substantially worldwide, suggesting the importance of
environmental/lifestyle risk factors and perhaps of their combina-
tion with genetic variants across racial/ethnic populations.
Patients diagnosed with localized prostate cancer are commonly
treated with a radical prostatectomy. Of these patients, 15%w46%
experience recurrence of disease as detected by a relapse in
prostate-speciﬁc antigen (PSA).2 Although several clinicopathologic
indicators, such as the PSA level, Gleason score, pathologic stage,an LLC. Open access under CC BY-NC-ND license.
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intended curative radical prostatectomy for localized prostate
cancer,3 new biomarkers are still needed to improve the prediction
of disease recurrence and selection of appropriate adjuvant thera-
pies for high-risk patients. DNA-based genetic biomarkers have
certain advantages over clinicopathologic indicators because they
can be preoperatively evaluated, are easily carried out, and are
interpreted more objectively without individual bias.
Because the prognostic signiﬁcance of genetic polymorphisms
on disease progression has produced promising results including
for prostate cancer, the purpose of the present article was to review
previous reports regarding the prognostic signiﬁcance of genetic
polymorphisms on PSA recurrence after a radical prostatectomy.
2. Materials and methods
The PubMed databasewas searched for related articles using the
keywords “genetic polymorphisms” and “radical prostatectomy”
from August 1985 to April 2011. Only articles in English and relating
to human participants were included in the current literature
review. Articles related to the keywords “genetic loci” and “PSA
recurrence” were additionally collected in this study.4 In total, 23
articles were identiﬁed and included in this mini-review.
3. Results
3.1. Prostate cancer susceptibility variants
Recently, numerous studies related to genome-wide association
studies identiﬁed several genetic variants associated with the risk
for prostate cancer in men of European ancestry.5e12 Although
these novel risk variants were replicated in several study pop-
ulations, knowledge of the associations of these risk variants with
the clinicopathologic features of prostate cancer is limited.
Our group systematically evaluated 20 prostate cancer-
associated single-nucleotide polymorphisms (SNPs) in a cohort of
320 patients with localized prostate cancer who had received
a radical prostatectomy.13 Three prostate cancer-susceptibility SNPs
(rs1447295 at 8q24, and rs7920517 and rs10993994 at 10q11) were
associated with PSA recurrence (p< 0.02). Of these, rs7920517 and
rs10993994 also showed signiﬁcant associations with a poor PSA-
free survival following a radical prostatectomy (log-rank test;
p< 0.01). The associations remained signiﬁcant in our multivariate
Cox proportional hazards analysis after adjusting for other clini-
copathologic risk covariates (p< 0.01).13
Subsequently, Gallagher and colleagues4 genotyped 798
patients of Ashkenazi Jewish ancestry who had received treatment
for localized prostate cancer and identiﬁed rs61752561 in KLK3 and
rs2735839 in the KLK2eKLK3 intergenic region as being strongly
associated with prostate cancer-speciﬁc survival, while rs10486567
in the 7JAZF1 gene was associated with biochemical recurrence [A/
A vs. G/G odds ratio (OR)¼ 1.89, 95% conﬁdence interval (CI)¼
1.31w2.74, p¼ 0.0007].4 However, they did not analyze the
predictive effect of rs10486567 after a radical prostatectomy or
radiotherapy separately4; thus, its predictive value toward PSA
recurrence after a radical prostatectomy remains unclear. Further-
more, Cheng and colleagues14 genotyped 26 SNPs that were
previously associated with prostate cancer risk among 788
(Caucasian) patients who were treated by a radical prostatectomy
or radiation therapy for aggressive prostate cancer. Among the 26
SNPs, ﬁve SNPs (rs12621278, rs629242, rs9364554, rs4430796, and
rs5945572) showed independent associations with prostate cancer
progression. When considering the sum of risk of alleles across
these ﬁve SNPs, each additional allele was associated with a 29%
increases in the risk of progression (95% CI¼ 1.12w1.47).14In addition, Whitman and colleagues15 also genotyped six SNPs
(rs1447295, rs6983561, rs13254738, Broad11934905, rs6983267,
and rs7000448) in three regions of chromosome 8q24 in 106
African-Americanmenwho had undergone a radical prostatectomy
for prostate cancer. They found that patients carrying the
Broad11934905 A risk allele, which is speciﬁc for African ancestry,
were more likely to have a higher pathologic stage (pT3-4) than
individuals with the wild type (OR¼ 4.48; 95% CI¼ 1.42w14.14;
p¼ 0.011). A trend toward an increased frequency of and a shorter
time to biochemical recurrence was noted in patients with this risk
allele from the Kaplan-Meier unadjusted survival analysis
(p¼ 0.076).15
Of importance, Morote and colleagues16 studied 83 prostate
cancer-related SNPs in 703 Caucasian patients and demonstrated
the improved prediction of biochemical recurrence (PSA recur-
rence) after a radical prostatectomy by genetic polymorphisms.16
They found that the model with the best ﬁt combined eight cova-
riates, including the ﬁve clinicopathologic variables of PSA, Gleason
score, pathological stage, lymph node involvement, and margin
status, and three SNPs of rs198977 in the KLK2, rs9282861 in
SULT1A1, and rs1536889 in the TLR4 gene. The model that was
based on clinicopathologic variables with SNPs showed signiﬁcant
improvement over the model without SNPs, as indicated by a 23.3%
net reclassiﬁcation improvement (p¼ 0.003), integrated discrimi-
nation index (p< 0.001), and likelihood ratio test (p< 0.001).
Internal validation proved the model robustness (bootstrap cor-
rected area under the receiver operating curve 0.78; range,
0.74w0.82). They concluded that predicting biochemical recur-
rence after a radical prostatectomy based on clinicopathologic data
can be signiﬁcantly improved by including the patient’s genetic
information.
3.2. Runt-related transcription factor 1 polymorphisms
The runt-related transcription factor (RUNX) family, also known
as acute myeloid leukemia (AML) and core-binding factor (CBF)-a,
consists of three DNA-binding a subunits, RUNX1, RUNX2, and
RUNX3. Interest in RUNX genes in cancer began with the discovery
that RUNX1 was an important translocation breakpoint in leuke-
mias, with TEL-RUNX1 fusion accounting for 20% of acute
lymphoblastic leukemias and the RUNX1-Eight-Twenty-One (ETO)
fusion accounting for 12% of AMLs.17
The present authors and their colleagues18 investigated the
association of RUNX1 rs2253319 with clinicopathologic character-
istics of prostate cancer and disease recurrence after a radical
prostatectomy. They found that the minor allele, T, and the minor
homozygous TT genotype of RUNX1 rs2253319 were signiﬁcantly
associated with a 1.49w2.76-fold higher risk for an advanced
pathologic stage and a 3.35w9.52-fold higher risk for lymph node
metastasis.18 The RUNX1 rs2253319 TT genotype was also associ-
ated with poorer PSA-free survival compared to the major homo-
zygote CC genotype in a Kaplan-Meier analysis (log-rank test,
p¼ 0.038) and multivariate Cox proportional hazards model
adjusted for age and PSA concentration (p¼ 0.045).18
3.3. SNPs in the Wnt pathway
Accumulated evidence has demonstrated signiﬁcant roles of the
Wnt pathway in the development and progression of human
prostate cancer.19 Adenomatous polyposis coli (APC) was originally
identiﬁed as a tumor suppressor gene in colon cancer. Loss of APC
interactions or activation of Wnt signaling leads to accumulation of
nuclear b-catenin (CTNNB1). This activates the transcription
factors, T-cell factor (TCF) and lymphoid enhancer factor (LEF),
which further activate targets controlling cell growth and
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a hospital-based, case-control study to comprehensively examine
the relationships of tagged SNPs and haplotypes in two key genes of
the Wnt pathway, APC and CTNNB1, with the localized prostate
cancer risk, clinicopathologic features, and biochemical failure after
a radical prostatectomy. They found that the APC rs3846716 GA/AA
genotypes were signiﬁcantly associated with a poorer PSA-free
survival (log-rank test, p¼ 0.037) compared with the GG
genotype.20
3.4. Tumor necrosis factor receptor superfamily member 11b
polymorphism
Prostate cancer is most likely to metastasize to the bone, and
bone metastasis was found to occur in approximately 90% of
prostate cancer-related deaths. A key molecular system that inﬂu-
ences bone remodeling consists of the tumor necrosis factor (TNF)
receptor superfamily member 11b (TNFRSF11B, also called osteo-
protegerin), receptor activator of nuclear factor-kB (RANK), and
RANK ligand (RANKL). TNFRSF11B prevents the association of
RANKL with RANK by acting as a decoy receptor.21 TNFRSF11B has
a wide tissue distribution and can be found in the normal prostate,
prostate tumors, prostate cancer bonemetastases, and stromal cells
of prostate tumors.
Recently, TNFRSF11B rs10505346 was implicated in prostate
cancer risk in the Cancer Genetic Markers of Susceptibility genome-
wide association study. The authors found that the mean level of
preoperative PSA and the relative risks of PSA recurrence after an
RPwere lower in individuals with the T allele than in thosewith the
G allele at TNFRSF11B rs10505346 (p¼ 0.019 and 0.014, respec-
tively). The T allele of rs10505346 remained a protective factor
against PSA recurrence (p¼ 0.022) in a multivariate Cox regression
model after considering all clinicopathologic risk factors except the
PSA level.22
3.5. SNPs in the p53 pathway
The tumor suppressor, p53, plays a crucial role in maintaining
genomic stability and tumor prevention. Mdm2 is one of the critical
regulators of the p53 protein. Jaboin and colleagues23 genotyped
Mdm2 SNP309 in 208 patients (98% Caucasian) who had undergone
a radical prostatectomy for prostate cancer and assessed its asso-
ciation with disease outcomes. They found that MDM2 SNP309
polymorphisms had no signiﬁcant association with race, patient
age at diagnosis, pre-prostatectomy PSA level, Gleason’s score,
surgical margin status, extracapsular extension, or disease stage.23
In addition, there was also no signiﬁcant difference in the 3-year
recurrence-free survival (RFS; p¼ 0.218) or 8-year overall survival
[(OS) p¼ 0.376).23
Another group assessed the potential prognostic roles of p53
codon 72 and XRCC1 codon 194, 280, and 399 polymorphisms on
the recurrence of PSA in clinically localized prostate cancer
(n¼ 126) after a radical prostatectomy.24 Of these three XRCC1
polymorphisms, codon 399 Arg/GlnþGln/Gn genotypes were
signiﬁcantly associated with a higher risk of PSA recurrence after
a radical prostatectomy compared with the Arg/Arg genotype
(34.0% vs. 15.1%, p¼ 0.013) and poorer PSA-free survival (log-rank
test, p¼ 0.0056).24 When considering other covariates in a Cox
proportional hazard model, the XRCC1 Arg/ Gln and Gln/Gln
genotypes [hazard ratio (HR)¼ 4.73; 95% CI¼ 1.61w13.92;
p¼ 0.005] and high Gleason score (Gleason score, 8w10;
HR¼ 5.58; 95% CI¼ 1.58w19.71; p¼ 0.008) were still independent
predictors of poor PSA-free survival after a radical prostatectomy.24
However, there were no similar signiﬁcant results for XRCC1
codons 194 or 280.243.6. SNPs in proinﬂammatory and anti-inﬂammatory cytokine
genes
Accumulating evidence indicates that chronic inﬂammation
may play an important role in the development of prostate cancer.
Chronic inﬂammationmay lead to tumorigenesis by damaging DNA
through radical oxygen and nitrogen species, enhancing cell
proliferation, and stimulating angiogenesis.25 In epidemiologic
studies, sexually transmitted infections and prostatitis contributed
to elevated PSA levels and were associated with prostate cancer
risk. However, nonsteroidal anti-inﬂammatory drugs seemed to
decrease the risk of prostate cancer.
Lin and colleagues26 assessed the potential prognostic roles of
interleukin (IL)-6, -8, and -10 polymorphisms on the recurrence of
PSA in clinically localized prostate cancer (n¼ 116, all Taiwanese)
after a radical prostatectomy. They chose those target genes
because all of them show important effects on the growth and
progression of prostate cancer in vitro and in vivo.26 They found
that the IL-6 polymorphism (rs2066992) T/G and G/G genotype
cases were associated with a higher percentage of preoperative
PSA levels of 10 ng/ml, a higher risk of a positive surgical margin,
and a higher risk of extraprostatic extension compared with the T/
T genotype.26 The IL-10 polymorphism (rs1800871) A/A genotype
was associated with a higher risk of PSA recurrence compared
with the A/GþG/G genotypes and signiﬁcantly poorer PSA-free
survival (log-rank test, p¼ 0.019).26 When considering other
covariates in a Cox proportional hazard model, the IL-10 A/A
genotype and a high Gleason score (of 8w10) were still indepen-
dent predictors of poor PSA-free survival (HR¼ 8.32, 95%
CI¼ 2.04w33.92, HR¼ 2.97, 95% CI¼ 1.07w8.23, p¼ 0.003 and
0.037, respectively).26 These results suggest that the IL-10 poly-
morphism might be a prognostic factor for PSA recurrence after
a radical prostatectomy.26
3.7. Fibroblast growth factor receptor 4 polymorphisms
Fibroblast growth factor receptor 4 (FGFR4) belongs to a family
of four transmembrane tyrosine kinase receptors (FGFR1w4) and is
activated by several members of the FGF family coupled with an
accessory molecule of heparin sulfate proteoglycan.27,28 FGFRs are
thought to play roles in such critical cellular processes as cell-cycle
regulation, migration, metabolism, survival, and cellular prolifera-
tion and differentiation.28 Findings suggested that rs351855,
a missense change at codon 388 (Gly388Arg) in the trans-
membrane domain of the FGFR4 gene, could play a role in tumor-
igenesis and progression of various cancers.
Wang and colleagues29 genotyped rs351855 in 329 cases (284
Caucasian and 45 African-American patients) who had undergone
a radical prostatectomy and 191 controls and found signiﬁcant
associations of the Arg allele with prostate cancer occurrence,
pelvic lymph node metastasis, and PSA recurrence. The frequency
of the Arg allele was signiﬁcantly higher in radical-prostatectomy
cases with lymph node metastases (p¼ 0.04) and PSA recurrence
(p¼ 0.02).29 A Matrigel assay was used to conﬁrm that Arg-
expressing cells displayed higher invasiveness than their Gly-
expressing counterparts.29 The increased motility and invasiveness
found in cells expressing Arg might be attributed to the associated
increase in urokinase type plasminogen activator receptor (uPAR),
part of the urokinase activator system which was suggested to
be involved in invasion and metastasis of prostate and other
cancers.29
FitzGerald and colleagues30 analyzed four tag SNPs, including
rs351855 and two other nonsynonymous SNPs, in and near the
FGFR4 gene in 1458 men with prostate cancer and 1352 age-
matched controls from a population-based case-control study.
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FGFR4 tag SNPs and prostate cancer risk overall or when consid-
ering disease aggressiveness, Gleason score, or tumor stage.30 They
suggested that the role of FGFR4 in disease risk and outcomes at
a population-based level appeared to be minor.30
3.8. Androgen receptor and androgen metabolism gene
polymorphisms
The androgen receptor is a ligand-dependent steroid hormone
transactivation factor. The transcription activation domain of the
androgen receptor is in the highly polymorphic N-terminal region
of exon l. Two trinucleotide repeats, CAG and GGC, which respec-
tively code for glutamine and glycine, are present. In vitro, the
absence of the polyglutamine tract is associated with higher tran-
scription activity, while an increase in the tract length is associated
with a decrease in activity.31 Short CAG repeats were shown to be
associated with the prostate cancer risk, and correlated with the
stage and grade at presentation.32,33
Nam and colleagues34 examined the signiﬁcance of the CAG
repeat polymorphism of the androgen receptor gene for predicting
prostate cancer progression among 318 patients treated with
a radical prostatectomy for clinically localized prostate cancer. They
found that overall, the CAG repeat allele was not predictive of
recurrence; however, in patients at low risk of recurrence (Gleason
score 2w6, stage pT2, and PSA  10 ng/ml), the relative risk of
recurrence associated with an allele of  18 CAG repeats was 8.07
(95% CI¼ 2.02w32.2, p¼ 0.004) compared with patients with an
allele length of> 18 CAG repeats.34 The biologic explanation for this
remains unclear.
3.9. 5a-Reductase type II polymorphism
The enzyme product of SRD5A2, 5a-reductase type II, is
responsible for converting testosterone to the more metabolically
active dihydrotestosterone. Therefore, SRD5A2 may be involved in
the development and growth of prostate tumors. Two single-base
substitution polymorphisms in SRD5A2, A49T and V89L, were
studied for their relevance in prostate carcinogenesis. Makridakis
and colleagues35 ﬁrst reported that men with one or two copies of
the V89L variant, which was more frequent in Asian men than in
African-American and Caucasian men, had lower 5a-reductase
activity than men with no V89L variant. However, case-control
studies showed no signiﬁcant association between the V89L poly-
morphism and prostate cancer risk.36e38 Makridakis and
colleagues39 subsequently reported that the T allele at codon 49
was associated with an increased prostate cancer risk in African-
American and Latino men, particular for advanced disease, even
though this association was not conﬁrmed in a study of Finnish
men.40 The A49T variant was also associated with an aggressive
phenotype of prostate cancer.41
Jaffe and colleagues41 genotyped 265 Caucasian men with
incidental prostate cancer who were treated with a radical pros-
tatectomy. They assessed the relationship of the A49T and V89L
polymorphisms at SRD5A2 with clinical and pathological tumor
characteristics of their patients. The presence of the A49T variant
was associated with a greater frequency of extracapsular disease
(OR¼ 3.16, 95% CI¼ 1.03w9.68) and a higher pathological
tumor-lymph node-metastasis (pTNM) stage (OR¼ 3.11; 95%
CI¼ 1.01w9.65).41 In addition, the A49T variant was over-
represented in two poor prognostic groups, which were correlated
with reduced rates of biochemical disease-free survival.41 Nam and
colleagues42 studied SRD5A2 V89L polymorphisms in 318 Canadian
men who had undergone a radical prostatectomy. They found that
the OR for progression in patients with at least one V allele (V/L orV/V) was 3.32 (95% CI¼ 1.67w6.62, p¼ 0.0006) compared with
patients with the L/L genotype.42 Sibata and coworkers43 subse-
quently conﬁrmed this ﬁnding in a study of 211 Caucasianmenwho
had undergone a radical prostatectomy. They found that the LL
genotype at the V89L site was associated with a statistically
signiﬁcant four to sixfold increase in PSA recurrence after adjusting
for clinicopathologic variables.433.10. Cytochrome P450 3A4 polymorphism
Cytochrome P450 3A4 (CYP3A4) is a protein belonging to the
cytochrome P450 supergene family. It is involved in the oxidative
deactivation of testosterone to biologically less active metabolites.44
A germline genetic variant in the 50-regulatory region of the CYP3A4
gene (A to G transition) on chromosome 7 was reported and named
CYP3A4*1B (alternate names include -392A>G and CYP3A4-V).
Previous biologic studies of this alteration reported little evidence
of altered function,45,46 but Rebbeck and coworkers47 found that
a genetic variant of CYP3A4 was associated with a higher clinical
grade and stage in white men with prostate cancer.
Powell and others48 assessed the predictive value of the CYP3A4
genetic variant and risk of recurrence after a radical prostatectomy
in 428 white men and 309 black (African-American) men. They
found that the stage, Gleason score, and preoperative PSA level
strongly predicted PFS but were not associated with CYP3A4
genotypes.48 There was a strong association between race and
genotype (p¼ 0.00002) in that 8% of white men and 83% of black
men had one or more copies of the G allele. When both races were
included, the genotype was associated with PFS (HR¼ 1.27,
CI¼ 1.08w1.27, p¼ 0.005).48 In race-speciﬁc analyses, increasing
copies of the G allele were associated with poorer PFS among white
men (HR¼ 1.98, CI¼ 1.06w3.70, p¼ 0.03) but had little impact on
PFS in African-American men (HR¼ 1.004, CI¼ 0.77w1.32,
p¼ 0.97).48 The authors also suggested that CYP3A4 might be one
of several biologic factors which are partly responsible for racial
disparities in prostate cancer.483.11. PSA polymorphism
PSA is an androgen-regulated serine protease and a member of
the tissue kallikrein family of proteases. It is produced by secretory
epithelial cells in acini and ducts of the prostate, and is secreted
directly into the lumen, where it functions to cleave semenogelin I/
II and proteins that mediate gel formation in semen.49 The gene
encoding the PSA is positively regulated by the androgen receptor
(AR). The AR is a steroid hormone receptor that binds as a homo-
dimer to speciﬁc DNA sequences, termed androgen-responsive
elements (AREs). At least 3 consensus AREs located at -156 to
-170 bp (base-pair) (ARE-I), -365 to -400 bp (ARE-II), and 4.2 kb
(ARE-III) from the transcriptional start site of the PSA gene were
identiﬁed.49 The -158A/G polymorphism with an adenine (A) to
guanine (G) substitution at position -158 of the PSA gene5 within
ARE-I was proposed to interact differently with the AR and thereby
modify the occurrence of prostate cancer. Although the allelic
frequency of the -158A/G polymorphism varies among different
ethnic populations, patients with the GG genotype are consistently
reported to be at increased risk of advanced prostate cancer.50e52
Chang and coworkers53 investigated the PSA -158A/G poly-
morphism in 122 Taiwanese patients with prostate cancer and 84
controls, and found that the GG genotype was also associated with
a larger tumor volume (2.34 vs. 0.82 ml) and higher pathologic
stage (68.2% vs. 31.8% organ-conﬁned cancer and 100% vs. 0%
extracapsular extension) than the GA and AA genotypes (p¼ 0.013
and 0.036, respectively).
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Vascular endothelial growth factor (VEGF), one of the most
potent angiogenic factors, was suggested to play a crucial role in
tumor neovascularization and was associated with tumor
progression and metastasis in prostate cancer.54 Fukuda and
colleagues55 assessed associations of the VEGF T-460C poly-
morphism with PSA recurrence in 95 Japanese patients who had
undergone a radical prostatectomy for prostate cancer and with the
survival of 99 patients withmetastasis at diagnosis. They found that
the CC and TC genotypes of the polymorphism were associated
with signiﬁcantly higher rates of PSA recurrence than the TT
genotype and were independent predictors of PSA recurrence (TC/
CC vs. TT, HR¼ 2.463, 95% CI¼ 1.233w4.926, p¼ 0.011) in a multi-
variate analysis.55 By contrast, metastatic prostate cancer patients
with the TT genotype showed signiﬁcantly worse survival
compared with the CC and TC genotypes.55 In a multivariate anal-
ysis, the TT genotype was an independent predictor of cancer-
speciﬁc survival (TT vs. TC/CC, HR¼ 2.976, 95% CI¼ 1.364w6.494,
p¼ 0.006).553.13. Epidermal growth factor receptor polymorphism
Approximately 39%w47% of prostate cancers express epidermal
growth factor receptor (EGFR).56 Increased expression was
observed during progression to advanced androgen-independent
stages.57 Mechanisms regulating EGFR gene expression are
complex and known to be affected by polymorphic variations.58
Perez and others59 studied nine haplotype tagging SNPs of the
VEGF in 212 patients (98.1% of whom were white) with clinically
localized prostate cancer treated with a radical prostatectomy.
There was a statistically signiﬁcant association between rs884419
and prostate cancer recurrence, as deﬁned in the study by at least
PSA biochemical recurrence (log rank test p< 0.001).59 In the Cox
proportional hazard regression model, patients carrying the G/G
and A/G genotypes were associated with a decreased risk of pros-
tate cancer recurrence compared to those with the A/A genotype
(HR¼ 0.094 and 0.130, 95% CI¼ 0.021w0.413 and 0.037w0.463,
p¼ 0.0018 and 0.0016, respectively).593.14. Mel-18 polymorphism
Mel-18, ofﬁcially termed PcG RING ﬁnger protein 2 (PCGF2), is
a member of the poly comb group (PcG) proteins, which are
chromatin regulatory factors and play important roles in devel-
opment and oncogenesis.60 A Mel-18 1805A/G SNP is located in
the 30 untranslated region and was predicted to alter the
secondary structure of messenger (m)RNA. Wang and colleagues
investigated Mel-18 polymorphism, expression, and clinical
signiﬁcance in 393 Japanese patients with prostate cancer and 146
controls. They found that patients with positive Mel-18 expression
had signiﬁcantly longer PSA RFS than patients who were negative
for Mel-18 expression (p¼ 0.038) (n¼ 131). Mel-18 mRNA
expression of the 1805A allele was signiﬁcantly higher than
expression of the 1805G allele. In a multivariate analysis,
a homozygous G allele genotype and negative Mel-18 expression
were independent risk factors predicting high PSA recurrence after
a radical prostatectomy, with respective HRs of 2.757 (p¼ 0.022)
and 2.271 (p¼ 0.045). Moreover, the G allele was also an inde-
pendent predictor of poor cancer-speciﬁc survival with an HR of
4.658 (GG/GA vs. AA, p¼ 0.019) for patients with stage D2 prostate
cancer (n¼ 66).3.15. Bcl2-938 polymorphism
B-cell lymphoma 2 (Bcl2) family proteins are mitochondrial
membrane proteins that are important regulators of programmed
cell death, i.e., apoptosis, in normal tissues and cancer cells. High
Bcl2 expressionwas reported to be associated with poor survival in
patients with prostate cancer.61
A novel functional SNP (-938C/A, rs2279115) was signiﬁcantly
associated with increased promoter activity and binding of nuclear
proteins compared to the A allele,62,63 resulting in overall decreased
bcl2 promoter transcriptional activity. Hirata and colleagues64
genotyped bcl2 (rs2279115) in 140 patients who had been treated
with a radical prostatectomy for prostate cancer. They found
a signiﬁcant difference in the biochemical recurrence-free time
between the bcl2 C/C and C/AþA/A genotypes.64 The bcl2 C/C
genotype was also noted to be an independent risk factor for
biochemical recurrence after a radical prostatectomy according to
a multivariate analysis (C/C vs. C/AþA/A, HR¼ 5.500, 95%
CI¼ 1.309w23.115, p¼ 0.019).64
3.16. Vitamin D receptor gene polymorphism
Vitamin D was related to prostate cancer risk in previous
epidemiologic studies and has antiproliferative, prodifferentiation,
and antimetastatic properties in experimental systems.65,66 Its
hormonal activity is mediated by the vitamin D receptor (VDR).
Several groups investigated whether germ-line genetic variations
in the VDR impact the progression of prostate cancer after a radical
prostatectomy.67e69
Williams and others69 analyzed VDR BsmI and TaqI poly-
morphisms of 428 white men and 310 African-American men who
had undergone a radical prostatectomy for localized prostate
cancer. However, among white men with locally advanced disease,
the BsmI B allele (absence of a restriction site) protected against the
recurrence in models examining the gene dose (p¼ 0.04) and
dominant effects (bbþ Bb) vs. BB, HR¼ 0.64, 95% CI¼ 0.41w1.00,
p¼ 0.05).69
In the 50 end of the VDR, there is a thymine/cytosine (T/C)
polymorphism in the ﬁrst two potential start (ATG) codons sepa-
rated by three codons. This polymorphism results in two alleles
that can be distinguished by a restriction fragment length poly-
morphism (RFLP) using the endonuclease, FokI. The F allele
(restriction site absent, ACG) lacks the ﬁrst ATG, so translation
begins at the second ATG, resulting in the VDR being shorter by
three amino acids than the f allele, which begins at the ﬁrst ATG.
The VDR FokI polymorphism was thought to be of functional
signiﬁcance. In addition, most data indicated that the F allele was
more effective than the f allele in transactivating the 1,25(OH)2D3
signal.70,71 The VDR FokI polymorphism is not in linkage dis-
equilibrium with the 30-end cluster of BsmI, ApaI, or TaqI
polymorphisms.
Xu and colleauges67 examined the association of the VDR FokI
genotype with histopathologic characteristics and prognoses of
prostate cancer among 191 patients who were mostly Caucasians
and who had undergone a radical prostatectomy. Patients with the
ff genotype had a lower mean percentage of Gleason grade 4/5
cancer (30.3%) than patients with the FF or Ff genotypes (42.8% and
43.8%, respectively; p¼ 0.015 by a t-test for ff vs. FFþ Ff).67 The data
suggested that the presence of an F allele increased the risk of being
diagnosed with more-aggressive cancer because a higher
percentage of Gleason grade 4/5 was found to be associated with
a worse prognosis.67 In a study of a Taiwanese population, the
authors of the present article found that the FF genotypewas highly
associated with more-aggressive prostate cancer [a Gleason score
of 8w10 (OR¼ 2.47; 95% CI¼ 1.20w5.08)] than were the Ff and ff
Y.-F. Tsai et al. / Urological Science 23 (2012) 35e4140genotypes.68 After adjusting for other covariates, they found that
the VDR FokI FF genotype was associated with a worse PSA RFS
(HR¼ 3.25, 95% CI¼ 1.32w8.00, p¼ 0.010) in patients who had
received a radical prostatectomy for localized prostate cancer
(n¼ 131).68
4. Conclusions
Genetic variants discovered from genome-wide association
studies and SNPs in important pathways on prostate cancer
occurrence and progression could serve as biomarkers for pre-
dicting PSA recurrence after a radical prostatectomy. Predicting PSA
recurrence after a radical prostatectomy may be improved by
including genetic information. Several studies were limited by the
sample size. More recent studies were conducted in only one
population, which might make those ﬁndings less able to be
generalized to other ethnic groups. Future studies should be dedi-
cated to conﬁrming these ﬁndings in other ethnical cohorts and
clarifying the roles of these SNPs/genes in the course of prostate
cancer progression after a radical prostatectomy thorough func-
tional analyses.
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